Education
About Us
Working with TipRanks
Follow Us
BioRestorative Therapies (BRTX)
NASDAQ:BRTX
Top Page
BioRestorative Therapies
(NASDAQ:BRTX)
45Neutral
Positive Factors
Clinical Data
MRI imaging data was the most compelling aspect, showing decreases in protrusion size and resolution of annular tears.
Market Potential
There is no existing competition in cervical spinal pain among MSCs, potentially making this opportunity larger than lumbar spinal pain.
Regulatory Approval
The ongoing Phase 2 trial in chronic lumbar disc disease (CLDD) recently received Fast Track designation from FDA.
Negative Factors
Competitive Landscape
Increasing regulatory acceptance of MSCs is noted, with other companies making advancements in this space.
Valuation Concerns
BioRestorative shares are seen as undervalued with a current market cap significantly lower than later-stage companies, suggesting room for valuation growth.
BioRestorative Therapies (BRTX) vs. S&P 500 (SPY)
Market Cap
$12.76M
Dividend YieldN/A
Average Volume (3M)226.81K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth175.03%
EPS Growth55.34%
CountryUS
Employees11
SectorHealthcare
Sector Strength76
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.20
Shares Outstanding7,504,780
10 Day Avg. Volume49,242
30 Day Avg. Volume226,810
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)32.31
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside370.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
BioRestorative Therapies Business Overview & Revenue Model
Company DescriptionBioRestorative Therapies (BRTX) is a biotechnology company focused on the development of innovative therapeutic solutions using cell and tissue therapies. The company operates primarily in the field of regenerative medicine, with a particular emphasis on stem cell-based therapies for the treatment of chronic lumbar disc disease and metabolic disorders. Its core products include BRTX-100, a stem cell-based therapeutic targeting disc/spine disease, and ThermoStem, a program focused on metabolic disorders including obesity and diabetes.
How the Company Makes MoneyBioRestorative Therapies generates revenue through the development and commercialization of its proprietary cell and tissue-based therapeutic products. The company aims to earn revenue by advancing its clinical programs through various stages of regulatory approval, ultimately leading to product commercialization and sales. Key revenue streams include potential licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies interested in its therapies. Additionally, BRTX may secure funding from grants and research subsidies as it progresses its clinical trials and expands its research initiatives. However, being a biotechnology company in the developmental stage, BioRestorative Therapies may also rely on equity financing and other forms of investment to support its operations until its therapies are fully developed and marketed.
BioRestorative Therapies Financial Statement Overview
Summary
BioRestorative Therapies is in a challenging financial position with consistent net losses and negative cash flows, despite some revenue growth. While the balance sheet shows reduced leverage and improved equity, the company's ability to generate cash and achieve profitability remains a significant concern. Continued focus on cost management and operational efficiency will be crucial for financial stability.Income Statement
BioRestorative Therapies shows a significant increase in revenue year-over-year, but it remains small in absolute terms. Despite this, the company struggles with negative profitability metrics, including persistent net losses and negative EBIT and EBITDA margins, indicating ongoing operational challenges and high costs relative to revenue.30
Negative
Balance Sheet
The company has improved its equity position with positive stockholders' equity, and it has no current total debt, reducing financial risk. However, the frequent large net losses impact the overall asset quality, and the equity ratio has been declining, signaling a need for better asset management.40
Negative
Cash Flow
Operating cash flow has been consistently negative, reflecting ongoing cash outflows from operations. While free cash flow has seen slight improvement, it remains negative, indicating cash burn. The reliance on financing activities to support cash needs is evident, which may not be sustainable long-term without improved operational cash generation.35
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 377.00K | 401.00K | 145.80K | 119.80K | 46.00K | 77.00K | Gross Profit |
| 266.84K | 372.93K | 145.80K | -160.87K | -159.21K | 77.00K | EBIT |
| -12.09M | -11.56M | -15.22M | -18.97M | -26.31M | -2.75M | EBITDA |
| -11.90M | -11.56M | -15.06M | -18.85M | -26.22M | -9.48M | Net Income Common Stockholders |
| -6.17M | -8.98M | -10.42M | -18.02M | -29.94M | -12.25M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 12.37M | 10.73M | 11.07M | 14.75M | 21.03M | 3.06M | Total Assets |
| 14.08M | 12.28M | 12.61M | 16.43M | 22.45M | 4.35M | Total Debt |
| 268.36K | 0.00 | 162.32K | 301.64K | 670.70K | 4.79M | Net Debt |
| -1.57M | -547.89K | -722.06K | -1.37M | -20.36M | 1.73M | Total Liabilities |
| 593.93K | 3.75M | 2.61M | 602.62K | 856.50K | 5.68M | Stockholders Equity |
| 13.49M | 8.53M | 10.00M | 15.83M | 21.60M | -1.33M |
| Cash Flow | Free Cash Flow | ||||
| -7.82M | -8.23M | -6.60M | -6.31M | -3.36M | -1.96M | Operating Cash Flow |
| -7.66M | -8.23M | -6.43M | -5.87M | -3.33M | -1.96M | Investing Cash Flow |
| -917.41K | 514.53K | 3.25M | -13.48M | -30.66K | 0.00 | Financing Cash Flow |
| 7.59M | 7.38M | 2.35M | 0.00 | 21.32M | 5.03M |
BioRestorative Therapies Technical Analysis
Negative
1.70
Price Trends
1.93
Negative
1.76
Negative
1.71
Negative
Market Momentum
>-0.01
Negative
49.88
Neutral
38.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRTX, the sentiment is Negative. The current price of 1.7 is below the 20-day moving average (MA) of 1.74, below the 50-day MA of 1.93, and below the 200-day MA of 1.71, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.88 is Neutral, neither overbought nor oversold. The STOCH value of 38.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRTX.
BioRestorative Therapies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $981.36M | ― | -6.14% | ― | -20.89% | 83.44% | |
48 Neutral | $6.36B | 1.09 | -49.92% | 2.63% | 17.17% | 0.95% | |
45 Neutral | $12.76M | ― | -96.89% | ― | 175.03% | 55.34% | |
42 Neutral | $3.24M | ― | -1703.39% | ― | ― | 90.33% | |
42 Neutral | $1.35B | ― | -21.26% | ― | ― | ― | |
40 Underperform | $193.31M | ― | -154.01% | ― | 187.79% | 32.40% | |
37 Underperform | $13.41M | ― | 249.03% | ― | 18.54% | 50.37% |
* Healthcare Sector Average
Performance Comparison
BRTX
BioRestorative Therapies
1.70
0.42
32.81%
PSTV
Plus Therapeutics
0.79
-1.10
-58.20%
MESO
Mesoblast
10.57
4.28
68.04%
BLFS
BioLife Solutions
20.88
3.57
20.62%
OCGN
Ocugen
0.66
-1.22
-64.89%
CNSP
CNS Pharmaceuticals
1.10
-558.90
-99.80%
BioRestorative Therapies Earnings Call Summary
Earnings Call Date: Mar 27, 2025 | % Change Since: -7.10% | Next Earnings Date: May 20, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth, improved financial performance, strong cash reserves, and promising clinical trial developments, including FDA Fast Track designation and expansion into new indications. However, ongoing financial losses and uncertain outcomes in potential licensing agreements were noted as challenges.Highlights
Record Revenue Growth
BioRestorative experienced a revenue growth of 175% year-over-year, reaching $401,000 for the 12-month period ending December 31, 2024.
Improved Financial Performance
The company's loss from operations was reduced by 24% from $15.2 million in 2023 to $11.6 million in 2024. Net loss also improved by 14% from $10.4 million in 2023 to $9 million in 2024.
Strong Financial Position
BioRestorative ended the year with $10.7 million in cash, cash equivalents, and marketable securities, with no outstanding debt.
Positive Clinical Trial Developments
In the ongoing Phase 2 trial for BRTX-100, no serious adverse events or dose-limiting toxicity were reported. Preliminary data indicated positive trends in treating chronic lumbar disc disease.
FDA Fast Track Designation
BRTX-100 received Fast Track designation from the FDA for chronic lumbar disc disease, facilitating development and expediting review.
Expansion into New Clinical Trial
The FDA cleared BioRestorative's IND application for a Phase 2 clinical trial targeting chronic cervical discogenic pain, making BRTX-100 the first stem cell product candidate cleared for this setting.
Innovative Preclinical Program
The ThermoStem program showed promise in preclinical studies, with significant reductions in weight and blood glucose levels in mice models.
Lowlights
Ongoing Financial Losses
Despite improvements, BioRestorative reported a net loss of $9 million for 2024.
Uncertain Licensing Outcomes
Discussions with a commercial stage regenerative medicine company regarding potential license agreements for ThermoStem are ongoing with no assurances of a successful agreement.
Company Guidance
During the BioRestorative Therapies 2024 Results Conference Call, key financial and operational metrics were shared. The company reported a 175% year-over-year revenue increase to $401,000 for the fiscal year ending December 31, 2024. They achieved a 24% improvement in loss from operations, reducing it to $11.6 million from $15.2 million in 2023. The net loss for 2024 was $9 million, or $1.16 per share, compared to $10.4 million, or $2.47 per share, in the previous year, marking a 14% improvement. Cash used in operating activities was $8.2 million, and the company ended the year with $10.7 million in cash, cash equivalents, and marketable securities, with no outstanding debt. The company also highlighted progress in their clinical programs, noting that their lead candidate BRTX-100 received FDA Fast Track designation and IND clearance for a Phase 2 trial targeting chronic cervical discogenic pain.BioRestorative Therapies Corporate Events
Regulatory Filings and Compliance
BioRestorative Clarifies Recent Press Release Details
Neutral
Mar 27, 2025
BioRestorative Therapies has released a statement clarifying that the information in their recent press release is being furnished and not filed, and will not be incorporated into any registration statement unless specifically identified. The company emphasizes that this does not constitute a determination or admission that the information is material or complete, nor should it be considered by investors for making investment decisions.
Regulatory Filings and Compliance
BioRestorative Therapies Issues Regulation FD Disclosure
Neutral
Feb 10, 2025
The news release does not contain specific information about BioRestorative Therapies’ industry, primary products or services, or market focus. The release appears to reference a Current Report on Form 8-K without providing substantial details about the company’s operations or implications for stakeholders.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.